| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | EC 6.1.1.21; HRS; HisRS; histidine translase; histidine-tRNA ligase |
| Entrez GeneID | 3035; |
| WB Predicted band size | 60kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from C-terminal of human HARS. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于HARS(组氨酰-tRNA合成酶)抗体的3篇代表性文献及其摘要概述：
1. **文献名称**：*Anti-histidyl-tRNA synthetase (Jo-1) antibodies in autoimmune myositis: Clinical and mechanistic insights*
**作者**：Cavazzana I, et al.
**摘要内容**：该研究探讨了抗Jo-1抗体(HARS抗体)在自身免疫性肌炎(如多发性肌炎和皮肌炎)中的临床意义。研究发现，该抗体与抗合成酶综合征密切相关，尤其是间质性肺病(ILD)和关节炎的并发症。研究还分析了抗体滴度与疾病活动度的关联性，提示其可作为预后监测的生物标志物。
2. **文献名称**：*The Diagnostic and Prognostic Value of Anti-Histidyl-tRNA Synthetase Antibodies in Idiopathic Inflammatory Myopathies*
**作者**：Meyer A, et al.
**摘要内容**：本文通过多中心队列研究，验证了抗HARS抗体在诊断特发性炎症性肌病中的特异性(>95%)，并强调了其在早期识别ILD和预测治疗反应中的作用。研究还发现，抗体阳性患者对免疫抑制剂(如利妥昔单抗)的反应更显著。
3. **文献名称**：*Molecular Mechanisms of Anti-Histidyl-tRNA Synthetase Antibody-Induced Lung Fibrosis*
**作者**：Nakashima R, et al.
**摘要内容**：该基础研究揭示了抗HARS抗体通过激活NF-κB信号通路和促炎细胞因子(如IL-6、TNF-α)的释放，导致肺成纤维细胞异常增殖和胶原沉积，从而促进间质性肺病的进展。实验模型进一步支持抗体直接参与肺纤维化病理过程。
---
以上文献均聚焦于抗HARS抗体的临床相关性、诊断价值及其在疾病机制中的作用，覆盖了从基础研究到临床应用的多维度分析。如需具体文献来源(期刊、年份)，可进一步补充关键词进行精确检索。
**Background of HARS Antibodies**
HARS (histidyl-tRNA synthetase) is an enzyme that catalyzes the attachment of histidine to its cognate tRNA during protein synthesis. As part of the aminoacyl-tRNA synthetase family, HARS is critical for translational fidelity. Autoantibodies targeting HARS, notably anti-Jo-1 antibodies, are hallmark biomarkers in anti-synthetase syndrome (ASS), a rare autoimmune disorder. ASS is characterized by clinical features such as interstitial lung disease, myositis, arthritis, and Raynaud’s phenomenon.
Anti-HARS antibodies are detected in approximately 20-30% of ASS cases, making them the most common antisynthetase autoantibodies. Their presence strongly correlates with myositis and pulmonary involvement, influencing disease prognosis and management. Mechanistically, these antibodies may arise from molecular mimicry or aberrant immune activation, though their exact pathogenic role remains debated. They are implicated in immune-mediated tissue damage, potentially through forming complexes with HARS that trigger inflammatory pathways.
Diagnostically, anti-HARS antibodies are identified via ELISA, immunoprecipitation, or line immunoassays. Their detection aids in differentiating ASS from other connective tissue diseases. Research continues to explore their role in disease heterogeneity, response to therapies, and potential as biomarkers for monitoring disease activity. Understanding HARS antibodies enhances insights into autoimmune pathogenesis and guides personalized treatment strategies.
×
